Helmholtz Diabetes Center
Institute for Diabetes and Obesity
Helmholtz Zentrum München
Prof. Matthias Tschoep
Matthias H. Tschöp received his M.D. from Ludwig-Maximilians University in Munich in 1994. After a residency in internal medicine and a fellowship in neuroendocrinology, Dr. Tschöp joined the Eli Lilly Research Laboratories where he discovered the orexigenic, adipogenic, and metabolic effects of ghrelin as well as its regulation by nutrients and body weight, establishing one of today’s fundamental pathways. He went on to join the University of Cincinnati, where he was the Arthur Russell Morgan Endowed Chair of Medicine. Together with his long-term collaborator Richard DiMarchi he established a series of novel gut hormone-based single molecule combinatorial therapeutics, several of which are now in clinical development for the treatment of diabetes and obesity. He currently serves as the Research Director of the Helmholtz Diabetes Center, Alexander-von-Humboldt Professor and Chair of Metabolic Diseases at Helmholtz Center and Technische Universität, Munich.
Director: Institute of Neuroscience and Medicine (INM-4)
Teamleader: MR Physics
Prof. Jon Shah
N. Jon Shah was born in Lahore, Pakistan in 1960. He received the M.S. degree in advanced studies in science from the University of Manchester, UK, in 1984 and the Ph.D. degree also from the University of Manchester, UK, in 1987.
After his Ph.D. he moved to the Toshiba R and D Center, Japan as a Postdoctorate Researcher (1987-1989) and from 1990-1992 he worked at the University of Cambridge and Addenbrooke’s Hospital Cambridge as a Research Associate. Then (1992-1995), he was a Clinical Scientist and Senior MR Physicist at Picker International GmbH and at the Herz- und Diabeteszentrum NRW in Germany. Since December 1995 he works at the Forschungszentrum Juelich GmbH in Germany. First as MR Group Leader and in 2008 he was appointed Director of the Institute of Neuroscience and Medicine – 4 at Forschungszentrum Juelich. From 2011-2012 he also held the position of Executive Director of the Institute of Neuroscience and Medicine. Parallel to his work in Juelich he was from 2004-2008 Professor of Experimental MRI (C3) at the University of Dortmund, Germany, and was appointed in July 2008 Professor of Physics of Magnetic Resonance in Neuroscience at RWTH Aachen University and in April 2010 Professor “Magnetic Resonance Physics” at Maastricht University.
He is the author of more than 200 articles, and more than 40 granted patents. His research interests include magnetic resonance imaging (techniques and hardware); ultra high-field MRI; hybrid MRI-PET; fMRI; neuroscientific applications of imaging. He is a member of the Editorial Board of the journal Brain Structure and Function.
N. Jon Shah was a recipient of a scholarship from the Japanese Association for the Advancement of Medical Equipment in 2001 and 2003.
Head of Research Group “Genetics of Metabolic & Reproductive Disorders”
Prof. Mathias Treier
Mathias Treier was born in Stuttgart, Germany in 1963. He received his diploma in Biochemistry from the University of Tübingen, Germany in 1990. He performed his PhD thesis at the European Molecular Biology Laboratory, EMBL, Heidelberg, Germany and received his PhD (Dr. rer. nat.) from the University of Heidelberg, Germany in 1994.
After his Ph.D. he moved to the Howard Hughes Medical Institute (HHMI), University of California, San Diego, USA to work as a Postdoctoral Fellow in the laboratory of Michael G. Rosenfeld (1995-1999). After that he became an Independent Group Leader at the European Molecular Biology Laboratory, EMBL, in Heidelberg, Germany, where he stayed from 2000-2009. In 2010 he became the Director of the Institute of Molecular Endocrinology and Full Professor for Molecular Mechanisms of Metabolic Diseases (W3), University of Cologne, Germany. In 2011 he was appointed Senior Group Leader at the Max-Delbrück Center for Molecular Medicine, the leading institute in its field in Germany. He holds at the same time the Chair for Experimental Metabolic Research (W3) at the Charité – University Medicine Berlin, the largest research hospital in Europe.
He is an internationally recognized mouse geneticist, who has generated multiple mouse models for human diseases and is especially interested in neuronal circuits of the central nervous system (CNS) that are involved in the (dys)regulation of energy homeostasis in obesity. With the brain-specific homeobox protein BSX Treier’s group identified an essential player marking a neuronal network within the hypothalamus that orchestrates eating behavior, sleep and higher cognitive functions (published in Cell Metabolism in 2007.
Head, Research Management
Institute for Diabetes and Obesity (IDO)
Helmholtz Zentrum München
Juliane Kampe, PhD
Dr. Kampe is a German nutrition biologist who trained at Potsdam University before entering neuroscience graduate school at the University of Cincinnati in 2004. Through collaborative ties with Monash University, she continued her graduate work in Melbourne, where she received her PhD in Neuroscience in 2009 at the Monash Obesity and Diabetes Institute (modi). As a graduate student in the Metabolic Neuroscience Group headed by Prof. Brian Oldfield in Melbourne she used pseudo-rabies virus tracing methods to elucidate body weight control circuits beyond the hypothalamus and later as a postdoctoral fellow in the same laboratory she established one of the first adjustable gastric band rodent models of bariatric surgery worldwide. She has published several peer-reviewed manuscripts including four frequently cited first author publications in Eur J Neuroscience, Obes Surg, Brain Res and Int J Obesity. Bringing experience as a former employee of Sanofi Aventis (2001-2003) she also served as the collaborative liaison between the metabolic neuroscience laboratory at Monash University and the US based pharmaceutical company, Allergan. After relocating back to Berlin in 2012 she accepted the position as the scientific manager of the Helmholtz Alliance ICEMED, where she is frequently commuting between Helmholtz offices in Munich and Berlin as well as visiting ICEMED partners nationwide.
Anja Marschner, PhD
Dr. Anja Marschner is a German pharmacologist who received her PhD degree in the department of Clinical Pharmacology headed by Prof. Dr. Stefan Endres at the medical faculty of the Ludwig Maximilian`s University (LMU) in Munich. Anja has gained extensive knowledge and experience in scientific program managment and coordination over the past 10 years working at Fresenius Biotech GmbH (now: Neovii Biotech GmbH) in the department of Medical Affairs. Key aspects of her previous position were to act as link between clinicians, scientists, and marketing representatives and to prepare scientific data for publication. Dr. Marschner joined the ICEMED program management team in May 2015 and is based at the coordinating Helmholtz Zentrum München. Anja is working closely with Juliane on all ongoing ICEMED-related activities, meetings, and reports.
Helmholtz Virtual Institutes
Helmholtz Association, Berlin Office
The Helmholtz Alliances offer participating scholars and scientists the opportunity to explore new research areas with the necessary critical mass or to further develop current research topics in innovative ways. Together with several universities and other external partners, the Alliances are organized in associations with international visibility. They are designed as self-managed networks, performing internationally acclaimed research. The Alliances promote young talents and pursue strategic appointment procedures while operating on the basis of an equal opportunity policy.
The Helmholtz Association contributes to solving grand challenges which face society, science and industry by performing top-rate research in strategic programmes in the fields of Energy, Earth and Environment, Health, Key Technologies, Structure of Matter, Aeronautics, Space and Transport.
The Helmholtz Association research systems of great complexity, with large-scale facilities and scientific infrastructures, cooperating closely with national and international partners. It contributes to shaping our future by combining research and technology development with perspectives for innovative applications and provisions for tomorrow’s world.